Payment overview · 2025
General Payments
$325.97
15 reported records · 8 companies
Healthcare provider profile · identity verified
Michael William Stumpf, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BATON ROUGE, LA · NPI 1023277530
Verified facts
What the public records show
CMS Open Payments records show Michael William Stumpf, M.D. received $325.97 in general payments during 2025 across 15 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.53 | 21.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $67.78 | 20.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $62.31 | 19.1% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $42.42 | 13.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.39 | 8.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.89 | 7.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.37 | 5.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.28 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $325.97 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.53 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $67.78 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $62.31 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 100 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 38 |
| Gabapentin | Gabapentin | 199 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 49 |
| Metformin Hcl | Metformin Hcl | 138 | 32 |
| Losartan Potassium | Losartan Potassium | 119 | 30 |
| Ozempic | Semaglutide | 116 | 22 |
| Lisinopril | Lisinopril | 107 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 40 |
| Levothyroxine Sodium | Levothyroxine Sodium | 80 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 21 |
| Allopurinol | Allopurinol | 49 | 13 |
| Carvedilol | Carvedilol | 49 | 17 |
| Spironolactone | Spironolactone | 48 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | suppressed |
| Omeprazole | Omeprazole | 47 | 18 |
| Potassium Chloride | Potassium Chloride | 47 | 12 |
| Trazodone Hcl | Trazodone Hcl | 47 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Meloxicam | Meloxicam | 42 | suppressed |
| Furosemide | Furosemide | 41 | 17 |
| Jardiance | Empagliflozin | 41 | 16 |
| Trulicity | Dulaglutide | 41 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 38 | 11 |
| Atrovent Hfa | Ipratropium Bromide | 37 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 24 |
| Metformin Hcl Er | Metformin Hcl | 35 | 18 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Eliquis | Apixaban | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 17 | 14 |
| Valsartan | Valsartan | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $325.97 · 15 records | Bayer Healthcare Pharmaceuticals Inc. | AREXVY, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, FREESTYLE LIBRE 3, GARDASIL 9, Kerendia, LEQVIO, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error